Last Updated: 16 Sep 2024
Executive Summary
Affimed NV (AFMD) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company's current market capitalization is $62.72 million, and its latest stock price is $4. Analysts have a strong buy rating on the stock, with an average target price of $24.44.
Company Overview
Affimed NV was founded in 2010 and is headquartered in Heidelberg, Germany. The company's mission is to develop and commercialize novel cancer immunotherapies that are safe, effective, and affordable. Affimed's lead product candidate is AFM13, a first-in-class antibody drug conjugate targeting CD30-positive hematologic malignancies.
Fundamental Analysis
Affimed NV's financial performance has been mixed in recent years. The company has reported losses in each of the past three years, and its revenue has declined in each of the past two years. However, the company's cash position has improved in recent quarters, and it has a strong pipeline of product candidates in development.
Technical Analysis
Affimed NV's stock price has been in a downtrend since early 2021. The stock is currently trading below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also in oversold territory, which suggests that the stock is due for a rebound.
Short Term Outlook
In the short term, Affimed NV's stock price is likely to be volatile. The stock could rebound from its current oversold levels, but it could also continue to decline if the company's financial performance does not improve.
Long Term Outlook
In the long term, Affimed NV's stock price is likely to be driven by the success of its product pipeline. If the company's lead product candidate, AFM13, is successful in clinical trials, the stock price could rise significantly. However, if AFM13 fails in clinical trials, the stock price could decline further.
Analyst Recommendations
Analysts have a strong buy rating on Affimed NV's stock. The average target price is $24.44, which represents a potential upside of over 500% from the current price.
